Genmab close to breaking news on potential blockbusters
Genmab is expected to release trial data on two potentially giant cancer drugs within the coming months, Danish business daily Børsen reports.
These are the two immunotherapies known as GEN 1042 and GEN 1046.
Jan van de Winkel, CEO of Genmab, said at an investor meeting in September that the company hopes to have data this year.
The data could be very crucial for the future valuation of the cancer drugs. Currently, the two cancer projects represent a relatively small value in analysts’ valuation of Genmab, because the risk of the projects is still high.
”If the data is a bit muddy and there are few indications where there is a better effect, then it may not be worth much, but if you can see a doubling of survival in lung cancer, then it is clear that Genmab immediately has a product that can sell for 5 billion dollars or more on its own,” says Danske Bank analyst Thomas Bowers in an interview with Børsen.
